[Carboplatin and radical radiotherapy in the treatment of locally advanced urinary bladder carcinoma].

Our prospective nonrandomized study included 46 patients with invasive urinary bladder carcinoma of the clinical T3a and b stages. The patients were treated by radical radiotherapy (65 Gy, conventional fractioning) and by Carboplatin (150 mg per week during radiotherapy; total 900 mg). Of 35 patients for whom the response was evaluated, the complete regression of tumor was reached in 85.71% and partial in 5.7% of patients. Hematological toxicity of I and II grade was seen in 36/46 of patients. The average follow-up time was 9 months (interval 4-15), overall one year survival rate was 85%, and disease-free survival was 87%. The results have shown that simultaneous application of radical radiotherapy and Carboplatine promises the improvement in the treatment of the invasive urinary bladder carcinoma, but the short follow-up time does not allow the definitive conclusions.